Treatment Clinical Trials for Prostate Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for prostate cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 276-300 of 316

  • Extended-Release Metformin for the Treatment of Prostate Cancer

    This phase II trial studies the effect of extended-release metformin in treating prostate cancer patients. PSA is a protein made by the prostate gland and found in the blood. PSA blood levels may be higher than normal in men who have prostate cancer, benign prostatic hyperplasia (BPH), or infection or inflammation of the prostate gland. PSA doubling time is the time, usually reported in months, that it takes for the PSA level to double in value. Current research shows that PSA doubling time is an important marker of disease progression and survival in men with prostate cancer. Faster doubling times are associated with negative disease outcomes. This trial may help researchers learn if extended-release metformin is an effective treatment to increase or prolong PSA doubling time or decrease PSA levels to prevent prostate cancer disease progression.
    Location: NYU Winthrop Hospital, Mineola, New York

  • Curcumin in Treating Patients with Prostate Cancer That Was Removed by Surgery

    This randomized phase II trial studies curcumin compared to placebo in treating patients with prostate cancer that was removed by surgery. Curcumin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help to decrease or prevent prostate cancer from returning after surgery.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas

  • Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

    This is a Phase 1, open-label, dose-escalation and expansion study evaluating the safety, tolerability, PK, antitumor activity, and effect on biomarkers of XL102 administered orally alone and in multiple combination regimens to subjects with advanced solid tumors.
    Location: 2 locations

  • HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    This study is a multinational Phase 3, randomized, double-blind, non-inferiority, efficacy and safety study of oral HC-1119 (80 mg / day) versus enzalutamide (160 mg / day) in asymptomatic or mildly symptomatic patients with progressive metastatic castration-resistant prostate cancer (mCRPC). The following assessment of prostate cancer status will be collected during the course of the trial: soft tissue disease on computed tomography (CT) scan or on magnetic resonance imaging (MRI), bone disease on radionuclide bone scans, FACT-P and EQ-5D, Brief Fatigue Inventory, and PSA. Throughout the study, safety and tolerability will be assessed by the recording of adverse events, monitoring of vital signs and physical examinations, safety laboratory evaluations, and 12-lead electrocardiograms (ECGs). Blood samples for population pharmacokinetics for HC-1119 and enzalutamide and related metabolites will be collected.
    Location: See Clinical

  • Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

    An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV) negative squamous cell carcinoma of head and neck that have failed to respond to standard therapy, progressed despite standard therapy, for which standard therapy does not offer the potential for increased survival.
    Location: See Clinical

  • Prostate Advances in Comparative Evidence

    This study is an international multicentre randomised study of organ confined low and intermediate risk prostate cancer and is composed of two parallel randomisation schemes based on applicability of surgery as a treatment for the patient. Patients for whom surgery is a consideration are randomised to either laparoscopic prostatectomy or prostate SBRT. Patients for whom surgery is not a consideration are randomised to either conventionally fractionated radiation therapy or prostate SBRT. Efficacy, toxicity and quality of life outcomes will be compared across the pairs in each randomisation.
    Location: See Clinical

  • Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

    This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

    Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) monotherapy or in combination with cemiplimab in patients with metastatic castration resistant prostate cancer (mCRPC: Part 1 and Part 2 Arms 1A and 1B) and in patients with high-risk, localized prostate cancer (LPC).
    Location: Banner University Medical Center - Tucson, Tucson, Arizona

  • First-in-Human Study of ICT01 in Patients With Advanced Cancer

    Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2-3 solid tumor indications and one hematologic malignancy for ICT01 monotherapy, and 1-2 solid tumor indication receiving ICT01 plus pembrolizumab.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Trial of NanoPac Focal Therapy for Prostate Cancer

    This study evaluates the use of NanoPac injected directly into the prostate lesion in men with prostate cancer.
    Location: University of Kansas Cancer Center, Kansas City, Kansas

  • ModraDoc006 / r vs Docetaxel IV in Metastatic Prostate Cancer

    This is a multicenter phase IIb study to evaluate the efficacy and tolerability of ModraDoc006 in combination with ritonavir (denoted ModraDoc006 / r) in patients with metastatic castration-resistant prostate cancer, suitable for treatment with a taxane.
    Location: See Clinical

  • To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

    Phase 1b - To assess the safety / tolerability of VERU-111 and to determine the maximum tolerated dose of VERU-111 in patients with metastatic, castration resistant prostate cancer who have failed a novel androgen blocking agent therapy (mCRPC). Phase 2 - To estimate the PSA50 response rate, defined as a decline in PSA to ≥50% of baseline level, confirmed with a second measurement at least 3 weeks apart (PCWG3).
    Location: See Clinical

  • Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

    Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.
    Location: See Clinical

  • Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol

    Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Using Virtual Reality (VR) Models for Robotic Prostatectomy

    A prospective, randomized, controlled study designed to assess whether digital virtual reality (VR) models, created from existing CT scans and MRIs, provide surgeons with an improved understanding of their patients' anatomy, resulting in more efficient operations (robotic prostatectomy) and improved patient care.
    Location: UC Irvine Health / Chao Family Comprehensive Cancer Center, Orange, California

  • Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance

    This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with localized prostate cancer. The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients. The researchers are interested in evaluating the proportion of participants with prostate cancer progression at 2 years following administration of Proscavax or active surveillance, the effect of the vaccine on prostate-specific antigen (PSA) doubling time and the assessment of adverse events in these patients. Eligible patients in this study will include men who are 18 years and older and who have a previously untreated early stage prostate cancer regardless of the date of diagnosis.
    Location: Beth Israel Deaconess Medical Center, Boston, Massachusetts

  • Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer

    Background: The ability to treat early prostate cancer is still limited. Thermal ablation methods are being tested for focal prostate cancer therapy. Researchers want to improve on these methods. Objective: To understand if Transurethral UltraSound Ablation (TULSA) in combination with MRI guidance is useful to treat localized prostate cancer. Eligibility: English-speaking adults ages 18 and older with localized prostate cancer that can be seen on MRI and can be treated by thermal ablation. Design: Participants will be screened with the following: - Medical history - Physical exam - Digital rectal exam - Blood and urine tests - Electrocardiogram - Tumor biopsy - Questionnaire to assess urinary tract symptoms - MRI of the pelvis. The MRI scanner is a long, narrow tube. Participants will lie on a bed that moves in and out of the scanner. Participants may also be screened with the following: - Echocardiogram - Chest x-ray - Bone scan - Urodynamic studies to see how well the bladder, sphincters, and urethra hold and release urine - MRI of the brain - Transrectal ultrasound - Computer tomography (CT) scan of the chest, abdomen, and pelvis. A CT scan is a series of x-ray images taken of parts of the body. Some screening tests will be repeated during the study. Participants will have the TULSA procedure. They will have an MRI for guidance. A small ultrasound applicator will be placed into their urethra. It uses heat to destroy the cancer areas in the prostate. It is controlled by a robotic arm. A cooling catheter will be placed into their rectum. Participants will use a urethral catheter for 1-7 days. Participants will have follow-up visits at 3, 6, 12, 18, 24, and 36 months.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

    This multicenter Phase I / II trial consists of two stages: a phase I stage in patients with castration resistant prostate cancer in which the recommended phase II dose will be determined for ipatasertib administered in combination with darolutamide; and a phase II neoadjuvant stage in which patients with high risk prostate cancer and loss of PTEN expression in the tumor tissue planning on undergoing prostatectomy receive ADT, darolutamide, and ipatasertib for 24 weeks prior to planned surgery.
    Location: Northwestern University, Chicago, Illinois

  • 177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

    The purpose of this study is to determine whether 177Lu-PSMA-617 improves the rPFS or death compared to a change in ARDT in mCRPC participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. Approximately 450 participants will be randomized (225 per treatment group).
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • ARX517 in Subjects With Advanced Solid Tumor

    A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced Solid Tumor Who Failed Prior Standard Therapies
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

    This study will treat patients with Metastatic Castration Resistant Prostate Cancer who have progressed following prior therapy. This is the first time this drug has ever been tested in patients, and so it will help to understand what type of side effects may occur with the drug treatment. It will also measure the the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • Focal Radiation Therapy, Androgen Deprivation Therapy, Abiraterone, Prednisone, and Olaparib for the Treatment of Castration-Sensitive Oligometastatic Prostate Cancer

    This phase II trial studies the effect of focal radiation therapy, androgen deprivation therapy (ADT), abiraterone, prednisone, and olaparib in treating patients with castration-sensitive prostate cancer that has spread to a few other places in the body (oligometastatic). Focal radiation therapy is a highly targeted way of delivering radiation to treat cancerous tumors. The technique allows radiation oncologists to deliver radiation from multiple directions. ADT is a hormone therapy. Prostate cancer cannot grow or survive without androgens, which include testosterone and other male hormones. This type of therapy decreases the amount of androgens in a patient's body which can slow the growth of the cancer and even shrink the tumor. Abiraterone works by decreasing the amount of certain hormones, including testosterone, in the body. It is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Prednisone is a steroid that is used to lessen inflammation and lower the body’s immune response. Olaparib is drug known as a PARP inhibitor. A PARP inhibitor is a substance that blocks an enzyme in cells called PARP. PARP helps repair deoxyribonucleic acid (DNA) when it becomes damaged. DNA damage may be caused by many things, including exposure to ultraviolet (UV) light, radiation, certain anticancer drugs, or other substances in the environment. In cancer treatment, blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. Giving focal radiation therapy, ADT, abiraterone, prednisone, and olaparib may help treat patients with castration-sensitive prostate cancer.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • A Supplement Containing Quercetin, Bromelain, Rye Flower Pollen, and Papain for the Reduction of Radiation-Induced Prostatitis

    This phase II trial studies the effect of a supplement containing quercetin, bromelain, rye flower pollen, and papain in reducing the severity of radiation-induced prostatitis. Low dose rate (LDR) brachytherapy, more commonly known as prostate “seed implant” involves permanent implementation of tiny radioactive sources into the prostate gland. These isotopes are usually palladium-131 or iodine-125. The radiation disappears over time (decays). High dose rate (HDR) brachytherapy involves the temporary implantation of a radioactive source (usually Iridium-192) that is then removed. Both HDR and LDR brachytherapy can cause inflammation of the prostate. Giving a supplement containing quercetin, bromelain, rye flower pollen, and papain may help relieve the symptoms associated with radiation induced brachytherapy.
    Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah

  • Abiraterone Acetate, Prednisone, Leuprolide, Niraparib, and Stereotactic Body Radiotherapy for the Treatment of High Risk or Node Positive Prostate Cancer, The ASCLEPIuS Trial

    This phase I / II trial investigates the best dose of niraparib and how well it works when given together with abiraterone acetate, prednisone, leuprolide, and stereotactic body radiotherapy in treating patients with high risk or node positive prostate cancer. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as niraparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Abiraterone acetate and leuprolide may fight prostate cancer by lowering the amount of testosterone made by the body. Anti-inflammatory drugs, such as prednisone lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Stereotactic body radiotherapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving niraparib together with abiraterone acetate, prednisone, leuprolide and stereotactic body radiotherapy may kill more tumor cells.
    Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

  • Single-Port Versus Multi-Port Robotic Radical Prostatectomy for the Treatment of Prostate Cancer

    This phase III trial compares the effect of single-port versus multi-port robotic radical prostatectomy in treating patients with prostate cancer. Single-port robotic radical prostatectomy is a surgery during which a single incision is made. Multi-port robotic radical prostatectomy is a surgery during which six small incisions are made. This study aims to understand whether a single incision surgery ends up with better recovery after surgery.
    Location: Case Comprehensive Cancer Center, Cleveland, Ohio